Spirocyclic degronimers for target protein degradation
申请人:C4 Therapeutics, Inc.
公开号:US10660968B2
公开(公告)日:2020-05-26
This invention provides compounds that have spirocyclic E3 Ubiquitin Ligase targeting moieties (Degrons), which can be used as is or linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.
INDOLINE DERIVATIVES AND THEIR USE AS 5-HT2 RECEPTOR LIGANDS
申请人:F. Hoffmann-La Roche AG
公开号:EP1328515B1
公开(公告)日:2008-08-06
SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION
申请人:C4 Therapeutics, Inc.
公开号:EP3454862A1
公开(公告)日:2019-03-20
Compounds and Compositions for the Treatment of Cancer
申请人:The Regents of the University of California
公开号:US20210009523A1
公开(公告)日:2021-01-14
The present disclosure provides compounds, pharmaceutical compositions, and methods for the treatment of cancer and fibrosis. The disclosed pharmaceutical compositions may include one or more pyrazolyl-containing compounds, or a derivative thereof.
[EN] SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION<br/>[FR] DÉGRONIMÈRES SPIROCYCLIQUES POUR LA DÉGRADATION DE PROTÉINES CIBLES
申请人:C4 THERAPEUTICS INC
公开号:WO2017197036A1
公开(公告)日:2017-11-16
This invention provides compounds that have spirocyclic E3 Ubiquitin Ligase targeting moieties (Degrons), which can be used as is or linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.